Aprea Therapeutics (NASDAQ:APRE) Shares Down 3.5% – Time to Sell?

Posted by Brenda Bartman on Oct 2nd, 2026

Aprea Therapeutics, Inc. (NASDAQ:APRE – Get Free Report) shares dropped 3.5% during trading on Thursday. The stock traded as low as $0.6750 and last traded at $0.7235. Approximately 772,588 shares changed hands during trading, an increase of 347% from the average daily volume of 172,868 shares. The stock had previously closed at $0.75.

Analyst Ratings Changes

Several research firms recently commented on APRE. Wedbush reduced their price objective on Aprea Therapeutics to $3.00 and set an “outperform” rating for the company in a research note on Thursday, August 13th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Aprea Therapeutics in a research note on Friday, July 17th. Three research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, Aprea Therapeutics presently has a consensus rating of “Hold” and an average price target of $3.07.

Read Our Latest Analysis on Aprea Therapeutics

Aprea Therapeutics Stock Performance

The company has a market cap of $9.11 million, a PE ratio of -0.67 and a beta of 1.66. The firm’s 50 day moving average is $0.73 and its 200-day moving average is $0.77.

Aprea Therapeutics (NASDAQ:APRE – Get Free Report) last released its earnings results on Wednesday, August 12th. The company reported ($0.07) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.18) by $0.11. On average, analysts predict that Aprea Therapeutics, Inc. will post -0.34 EPS for the current year.

Hedge Funds Weigh In On Aprea Therapeutics

A hedge fund recently raised its stake in Aprea Therapeutics stock. AIGH Capital Management LLC raised its stake in Aprea Therapeutics, Inc. (NASDAQ:APRE – Free Report) by 174.1% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,015,541 shares of the company’s stock after buying an additional 645,000 shares during the quarter. AIGH Capital Management LLC owned approximately 8.47% of Aprea Therapeutics worth $775,000 at the end of the most recent quarter. 34.19% of the stock is owned by hedge funds and other institutional investors.

Aprea Therapeutics Company Profile

(Get Free Report)

Aprea Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cancer. The company’s research centers on restoring the function of mutated p53, a tumor-suppressor protein that is altered in many cancers and plays an important role in regulating cell growth and programmed cell death.

Aprea’s pipeline has included eprenetapopt (APR-246), an investigational therapy designed to reactivate mutant p53, as well as next-generation p53-reactivating compounds such as APR-548.